Skip to main content
Clinical Trials/DRKS00021765
DRKS00021765
Completed
Not Applicable

Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer – a propensity score matched analysis

Klinikum der Universität München AVT Chirurgie0 sites82 target enrollmentMay 25, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C25
Sponsor
Klinikum der Universität München AVT Chirurgie
Enrollment
82
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 25, 2020
End Date
April 2, 2020
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinikum der Universität München AVT Chirurgie

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing pancreatic surgery at our institution between 01/2014 and 11/2016 .
  • Inclusion criteria were: (1\) confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) by pathology, (2\) exclusion of distant metastasis at time of surgery, (3\) successful resection of primary tumor with curative intent, (4\) postoperative survival and/or follow\-up of at least 12 weeks, (5\) disease\-free survival of at least 6 weeks. Since we wanted to focus our analysis on the metastases that might be favored by the perioperative period, we excluded patients who developed metastases within the first 6 weeks after resection, as these must have presumably already existed at the time of surgery.

Exclusion Criteria

  • Patients with diagnosis other than PDAC were excluded as well as patients that suffered from locally advanced disease that underwent neoadjuvant therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials